TrimSpa’s future?
This article was originally published in The Tan Sheet
Executive Summary
Goen Technologies, subsidiary company TrimSpa Inc. and its recently deceased spokesperson, Anna Nicole Smith, were named in a class-action lawsuit alleging false and misleading marketing for the TrimSpa X32 weight-loss supplement. The suit was filed Feb. 5 in the California Superior Court of Los Angeles County. Plaintiffs are asking for unspecified damages, restitution and an injunction preventing TrimSpa from making future weight-loss claims. The class action suit quickly follows Goen Technologies' and related marketers' $1.5 mil. settlement with FTC over allegations of unsubstantiated weight-loss claims (1"The Tan Sheet" Jan. 8, 2007, p. 4). TrimSpa's recent legal trouble in conjunction with Smith's death does not bode well for the future of the brand, according to brand consultant Robert K. Passikoff, Ph.D. Not only does the combination of circumstances deliver "too big a hit" for TrimSpa to recover, but there may also be reverberations across the entire weight-loss supplement category, Passikoff said....
You may also be interested in...
FTC Supplement Settlements Spotlight Bayer, Mark First Hoodia Action
Bayer "went too far" with weight-loss and -control claims for its One-A-Day WeightSmart product and violated a 1991 sanction the product's previous owner agreed to, the Federal Trade Commission said Jan. 4 when it announced a record $3.2 million fine against the consumer healthcare giant
Submitting A Non-COVID-19 Product For FDA Review? Then Take A Seat, It’s Gonna Be Awhile
Top US FDA officials Jeff Shuren and William Maisel said in a 15 April blog post that manufacturers should expect a delay in the review of new product submissions thanks to the pandemic. They noted that the agency also won’t be accepting certain IVD pre-submission requests until next year.
Prescience Point Capital Launches Proxy Fight To Change MiMedx's Board
Prescience Point Capital is trying to reshuffle the board of directors leading regenerative medicine company MiMedx, arguing the company’s current board has destroyed shareholder value. The company's tock is selling for about a third of its potential value, according to Prescience.